key: cord-0775910-j420hecf authors: Nevermann, Nora; Wiering, Leke; Wu, Helen; Moroder, Philipp; Brandl, Andreas; Globke, Brigitta; Krenzien, Felix; Raschzok, Nathanael; Schöning, Wenzel; Lurje, Georg; Öllinger, Robert; Schmelzle, Moritz; Pratschke, Johann; Ritschl, Paul Viktor title: Transplantation programs facing lack of empirical evidence on SARS‐CoV‐2 vaccination: A society recommendation consensus update date: 2021-07-28 journal: Transpl Infect Dis DOI: 10.1111/tid.13696 sha: c6e491e42f2ef54a475da188d20d86a571fc3c2e doc_id: 775910 cord_uid: j420hecf BACKGROUND: Since phase III trials for the most prominent vaccines excluded immunocompromised or immunosuppressed patients, data on safety and efficacy of SARS‐CoV‐2 vaccines for recipients of solid organ transplantations are scarce. AIMS: Our study offers a synthesis of expert opinions aligned with available data addressing key questions of the clinical management of SARS‐CoV‐2 vaccinations for transplant patients. METHOD: An online research was performed retrieving available recommendations by national and international transplantation organizations and state institutions on SARS‐CoV2 vaccination management for transplant recipients. RESULTS: Eleven key statements were identified from recommendations by 18 national and international societies, and consensus for the individual statements was evaluated by means of the Society Recommendation Consensus score. The highest consensus level (SRC A) was found for prioritized access to vaccination for transplant patients despite anticipation of a weakened immune response. All currently authorized vaccines can be considered safe for transplant patients (SRC A). The handling of immunosuppressive medication, the timely management of vaccines, and other aspects were aligned with available expert opinions. CONCLUSION: Expert consensus can be determined for crucial aspects of the implementation of SARS‐CoV‐2 vaccination programs. We hereby offer a tool for immediate decision‐making until empirical data becomes available. Accordingly, all consenting recommendations were represented by one point and added up. Dissenting recommendations were subtracted (value of -1) from the number of societies supporting the recommendation. Partial consent or a recommendation for a case-by-case decision was marked as "partial agreement" and represented by 0 points. Missing comments of individual societies on a specific topic were marked as "not available (n.a.)" and represented by 0 points. A "strong" recommendation was defined as consensus within >50% of society recommendations (SRC A) and "medium" and "low" recommendation as consensus of >25% and <25% of retrieved recommendations (SRC B and C). No ethical approval was necessary as all information is accessible online. Recommendations or statements by 18 national and international societies were retrieved (Table 1 for according sources and links). Eleven key statements were defined and are listed in Table 2 . The statements were then categorized according to the SCR-category A (strong consensus), B (medium consensus), and C (low consensus). Details of the SRC score calculation are provided in Figure 1 . Individual statements are discussed hereafter. Donors with prior SARS-CoV-2 infection can be considered for donation after clearance of infection A strong consensus was found that prior SARS-CoV-2 infection does not constitute a contraindication for organ donation. The American Society of Transplantation (AST) requires a timely delay of 21 days between initial COVID-19 symptoms in addition to repeated negative PCR testing. 5 Additionally, the German Organ Transplantation Foundation (DSO) requires the absence of clinical symptoms and no radiologic signs of pulmonary manifestation of COVID-19. 6 The Canadian Society of Transplantation (CST) suggests a 4-week period after the first positive PCR test. 7 The British National Health Service demands a case-bycase decision after moderate and severe COVID-19 (defined as need for hospitalization) assuming chronic end-organ damage. 8 In contrast, the Chinese government issued a statement that prior SARS-CoV-2 infection is to be considered a contraindication and negative antibody results (IgG and IgM) are required before organ retrieval. 9 Recommendation with medium consensus (SRC B) 6 Vaccination respecting a timely delay of 2 weeks prior to transplantation and 4 weeks after transplantation should be favored. Positions of individual societies were defined as "consenting" (mark-up: green, attributed value: +1), "dissenting" (mark-up: red, attributed value: −1), "case-by-case decision/partial agreement" (mark-up: orange, attributed value: 0), or "not discussed" (mark-up: white, attributed value: 0). SRC categories were defined as strong = A (>50% of the societies support the statement); medium = B (25%-50% of the societies support the statement), low recommendation = C (<25% of the societies support the statement) Abbreviation: SCR, Society Recommendation Consensus. Merely 0.6% of the 100.000 participants included in the vaccines' clinical trials of Pfizer and Moderna presented preexisting liver or kidney disease (excluded in the AstraZeneca trial). 12 Immunocompromised or immunosuppressed patients were excluded by all three vaccine trials. A first cohort study including 187 SOT recipients describes mild vaccine-related reactions as expected and no episode of acute rejection, COVID-19 outbreak, or other severe secondary reactions. 17 Faced with insufficient evidence, a strong expert opinion consensus can be found to classify all currently authorized vaccines (mRNA and adenovirus vector based) as safe for use in immunosuppressed patients. Vaccines based on inactivated coronaviruses (e.g., CoVaxin, Bharat Biotech; BBIBP-CorV, Sinopharm) are proposed to be contraindicated for immunosuppressed patients, but currently no vaccine of this group gained emergency use authorization. 18 As discussed by the Japanese Transplantation Society, merely 5% of the phase III trial population is of Asian ethnicity leaving an uncertain risk of a non-representative cohort even for the general population. 14 For a first cohort of 436 vaccinated transplant recipients, a detectable antibody titer at 20 days after the first injection was detected in 17% of participants. 17, 19 A recent study that compared the antibody response of 34 SOT (kidney and heart transplantations) and 116 health care workers found a significantly lower response rate of 58.8% versus 100% (median titers: 1370 vs. 11710, p < 0.001). 20 Anti-metabolite immunosuppression (AMI) therapy (33% in those receiving AMI vs. 79%) and high dose corticosteroids in the last 12 months were found to be associated with low antibody response. 20,21 A second study (136 kidney recipients and 25 health controls) confirms a lower response rate (37% vs. 100% with a lower anti-spike level. 21 Several transplant societies (e.g., NTS, Netherlands) favor the use of RNA-based vaccines as a higher efficacy for elderly people -with presumed lower immunogenicity -was shown and to avoid the theoretical risk of replication of the vector virus -per se replication deficient -in a (strongly) immunosuppressed patient. 6, 22 Attenuated immune response for cirrhotic patients is well described, 23 but the high risk of severe COVID-19 may nevertheless justify prioritized vaccination of immunosuppressed patients and patients awaiting transplantation. Transplantation should not be postponed due to vaccination schedules (SRC A) Furthermore, a strong consensus was found with regard to prioritizing transplantation over vaccination. The absence of a vaccination should not contraindicate or delay a transplantation. 22 Excluding patients from transplantation after vaccination with a live attenuated vaccine is discussed in Germany. 6 Up-to-date, no SARS-CoV-2 vaccine of this category gained authorization. The Pan-London Transplant Collaborative Ethics Group discusses handling of individuals that refuse SARS-CoV-2 vaccination -potentially up to 40% of the population 24 -stating that, in case of additional risk factors for severe COVID-19 infections and as long as transmission rates are high, it may not be appropriate to perform transplantation in the absence of vaccination. 25 Recommendations with medium consensus (SCR B) Vaccination respecting a timely delay of 2 weeks prior to transplantation and 4 weeks after transplantation should be favored Consensus was found for respecting a delay of 2 weeks prior to transplantation (if transplantation date is foreseeable) and 4 weeks posttransplantation, in analog to recommendations for other vaccines. 26 A longer time stretch since (kidney) transplantation was shown to correlate with seroconversion after SARS-CoV-2 vaccination compared to the non-seroconverted group (15.4 vs. 5.8 months). 27 Furthermore, anti-metabolite maintenance immunosuppression was associated with a low seroconversion rate. Clear evidence on the effects of specific immunosuppression regimens of vaccine response is pending. Reduced vaccine immunogenicity after liver transplantations is well evaluated for hepatitis A and B virus, and pneumococcal and influenza vaccines. 28 Likewise, prioritized vaccination of patients on transplant waiting lists should be considered. Up to now, the correlation between antibody titers and clinical immunity against COVID-19 remains uncertain. Two publications describe a less frequent antibody response of transplant recipients after SARS-CoV-2 vaccination (10.8% for kidney transplant recipients and 17% for a heterogenous transplant cohort at 20 days after injection of the first dose), 17, 19 but as stated by the Dutch Transplant Foundation (NTS), the correlation of clinical immunity with a certain antibody titer is not yet defined. 29 In addition, the influence of the T cell-mediated immune response remains unclear and is not necessarily correlated with SARS-CoV-2 antibody titers. 30 Furthermore, the amplitude and duration of vaccine response as well as the duration of the response after transplantation remain to be assessed. As described above and in opposition to a strong consensus, the Chinese transplantation program demands negative antibody testing before organ retrieval. 9 In contrast to the clinical use of antibody testing, clinical and biological monitoring and empirical evaluation of immune response rates is defined as a crucial task by the DSO. 6 In case of T-/ or B-cell depleting immunosuppression, a delay of 3 months until vaccination can be recommended Consensus was found in anticipating a drastically reduced immunogenicity after T-or B-cell depletion and therefore shifting the benefit and risk of a vaccination. A delay of 3 months (AST, US) up to 6 months (ABM, France) until vaccination can thus be recommended. 5, 22 The AST also postulates a reduction or loss of pretransplant immunity after transplantation especially after T-/B-cell depleting immunosuppression. 5 Further data are pending. A delay of 2 weeks between SARS-CoV-2 vaccination and other vaccinations can be recommended Consensus was found for a 2-week delay between reception of a SARS-CoV-2 vaccine and other vaccinations including the seasonal influenza vaccine. 14, 22 The pursuit of a complete SARS-CoV-2 vaccination is to be prioritized over the influenza vaccine. Recommendations with low consensus (SCR C) Immunosuppression should not be suspended or reduced during the process of vaccination Plural transplant societies recommend to maintain immunosuppression during the process of vaccination. Even though immunosuppression and especially antimetabolites may be associated with lower antibody response after vaccination, 31,32 the data are widely insufficient to justify taking any risk of rejection and disturbed transplant function. After treatment of an acute rejection, a delay until vaccination can be recommended Analogous to general vaccination recommendations, vaccination during active treatment for rejection should be avoided. 26 The CST proposes a 4-week delay until SARS-CoV-2 vaccination, the Spanish Society of Transplantation at least 2 weeks. 7, 33 No elevated risk of rejection post-SARS-CoV-2 vaccination is to be expected. Such concerns have previously been raised especially in the context of the 2009 H1N1 influenza vaccines containing ASO3 adjuvant but were discarded by reviews. 34 At the present time, SARS-CoV-2 vaccination seems to be the key in controlling the SARS-CoV-2 pandemic. Once again, the high dynamic of this outbreak raises medical questions which as of yet cannot be answered by evidence-based findings. Currently, the implementation of vaccination programs for the high-risk group of transplant patients constitutes a time-sensitive task. The concept of SRC was designed during the first wave of the COVID-19 pandemic to facilitate immediate decision-making when facing a lack of evidence-based guidelines. We hereby offer a temporary approach for addressing crucial questions concerning SARS-CoV-2 vaccines for SOT recipients until evidence becomes available. Homogenous recommendations were found for several key questions, cf. Interestingly, first findings indicate that the higher risk of severe COVID-19 within SOT recipients is rather associated with the profile of preexisting conditions rather than the transplantation itself or the intake of immunosuppressive medication. 35 Accordingly, a high mortality of patients on transplantation waiting lists of 25.8% has been reported. 13 Put in the context of the expert consensus anticipating lower immunogenity after transplantation, prioritized vaccination of waitlisted patients -as proposed by several expert societies 5,15,22seems highly beneficial. Furthermore, vaccination of household members was proposed by several transplant societies and can serve as a mechanism to counterbalance a lower vaccination success rate. 5, 14, 15 The role of immunosuppressive medication within the course of a SARS-CoV-2 infection and vaccination remains unclear, and further data are urgently needed. 35 According to the expert consensus, immunosuppressive medication should be continued during the vaccination process (SRC C). The guiding principles provided for in this paper are severely lim- after full vaccine-immunization. 37 In this context, special attention should be paid to the attenuated immune response of transplant recipients. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Solid organ transplantation programs facing lack of empiric evidence in the COVID-19 pandemic: a By-proxy Society Recommendation Consensus approach American Society of Transplantation German Organ Transplantation Foundation Consensus guidance and recommendations for organ donation and transplantation services during COVID-19 pandemic. Canadian Society of Transplantation 2 vaccination in adult solid organ and islet transplant wait-listed patients and adult living donor transplant recipients. British National Health Service Guangming L Expert consensus on the normalization of epidemic prevention and control and biosafety management in designated hospitals for novel coronavirus pneumonia carrying out liver transplantation An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question SARS-CoV-2 infection and early mortality of waitlisted and solid organ transplant recipients in England: a national cohort study Vaccine Committee, Japan Society for Infectious Diseases COVID-19 Vaccine Recommendations SARS-CoV-2) causing COVID-19: Information for donation and transplant professionals Update on vaccinations for SOT recipients Safety of the first dose of SARS-CoV-2 vaccination in solid organ transplant recipients COVID-19 vaccination in our transplant recipients: the time is now Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients Reduced humoral response to mRNA SARS-Cov-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus Effectiveness of influenza vaccines in adults with chronic liver disease: a systematic review and meta-analysis Attitudes toward a potential SARS-CoV-2 vaccine : a survey of U.S. adults Kidney transplantation and patients who decline SARS-CoV-2 vaccination Vaccination of solid organ transplant candidates and recipients: guidelines from the American society of transplantation infectious diseases community of practice Weak anti-severe acute respiratory syndrome coronavirus 2 antibody response after the first injection of an mRNA coronavirus disease 2019 vaccine in kidney transplant recipients A comprehensive review of immunization practices in solid organ transplant and hematopoietic stem cell transplant recipients COVID-19-vaccinatie van immuungecompromitteerde patiënten. Dutch Transplant Foundation COVID-19 en vaccinatiebeleid COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses Mycophenolate and lower graft function reduce the seroresponse of kidney transplant recipients to pandemic H1N1 vaccination Live vaccines after pediatric solid organ transplant: proceedings of a consensus meeting Recomendaciones FACME para la vacunación frente a COVID-19 en grupos de potencial riesgo Effect of the adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine on the risk of rejection in solid organ transplant recipients in England: a self-controlled case series COVID-19 and solid organ transplantation: a review article Prospective mapping of viral mutations that escape antibodies used to treat COVID-19 SARS-CoV-2 infection after vaccination in health care workers in California Transplantation programs facing lack of empirical evidence on SARS-CoV-2 vaccination: A society recommendation consensus update The current lack of evidence demands systematic scientific monitoring of safety and efficacy of performed vaccination of transplant recipients and patients awaiting transplantation.